Diagnosing adenosquamous cell lung cancer stage IV requires a careful combination of imaging studies, tissue analysis, and molecular testing to confirm the presence of this rare mixed-type lung cancer and determine how far it has spread throughout the body.
Introduction: Who Should Undergo Diagnostics
Stage IV adenosquamous cell lung cancer is a condition where diagnosis becomes especially important because the cancer has already spread beyond the lungs to other parts of the body. People who should consider seeking diagnostic evaluation include those experiencing symptoms such as persistent coughing, shortness of breath, chest pain, or unexplained weight loss. Current or former smokers, particularly those over the age of 70, face higher risk and should be especially attentive to these warning signs.[1][2]
It’s important to understand that adenosquamous carcinoma (which means a cancer containing both gland-forming cells and flat, scale-like cells) represents a relatively uncommon form of lung cancer, accounting for only about 2% to 4% of all lung cancer cases. Because this type tends to be more aggressive than typical lung cancers, early medical consultation when symptoms appear can make a difference in the treatment options available.[4]
Anyone with a family history of lung cancer, long-term exposure to tobacco smoke, or other known risk factors should maintain regular contact with their healthcare provider. For those already living with lung cancer of another type, any new symptoms or changes in health status warrant immediate medical attention, as the nature of the cancer can sometimes change over time.[4]
Classic Diagnostic Methods
Diagnosing adenosquamous carcinoma of the lung presents unique challenges because this cancer contains a mixture of two different cell types. This mixed nature means that getting the complete picture often requires more extensive testing than for other lung cancers. The journey toward diagnosis typically begins with imaging studies that can reveal suspicious areas in the lungs and show whether cancer has spread to other locations in the body.[2]
Imaging Tests
The first step usually involves a chest X-ray, which can reveal abnormal masses or nodules in the lungs. However, because adenosquamous carcinoma requires detailed examination, doctors typically order more advanced imaging studies. A CT scan (computed tomography) provides cross-sectional images of the chest and can show the size, shape, and location of tumors, as well as whether nearby lymph nodes appear enlarged. These detailed images help doctors plan the next steps in diagnosis and understand how extensive the cancer might be.[2]
For stage IV disease, where cancer has spread to distant organs, additional imaging becomes necessary. PET scans (positron emission tomography) can detect areas of increased metabolic activity throughout the body, helping identify whether cancer has spread to bones, the liver, the brain, or other organs. Sometimes doctors combine PET with CT scanning for even more detailed information. An MRI (magnetic resonance imaging) might be ordered specifically to examine the brain or other soft tissues in detail.[2]
Biopsy and Tissue Analysis
While imaging tests can show where tumors are located, only a biopsy (the removal of a small sample of tissue for examination) can definitively confirm the diagnosis of adenosquamous carcinoma. This is particularly crucial because this cancer type contains both adenocarcinoma cells (which form gland-like structures) and squamous cell carcinoma cells (which are flat and scale-like). Doctors need to examine tissue under a microscope to identify both components.[1][4]
Getting an accurate diagnosis before surgery can be extremely difficult with adenosquamous carcinoma. Studies have shown that this cancer is misdiagnosed as either pure adenocarcinoma or pure squamous cell carcinoma in at least half of cases when doctors rely only on small biopsy samples. In some research, nearly all cases (98%) were either misdiagnosed or went undiagnosed before surgical removal of the tumor.[4]
Several types of biopsies might be performed depending on where the tumor is located. A bronchoscopy involves passing a thin, flexible tube with a camera through the airways to reach the tumor and collect tissue samples. Needle biopsy uses a thin needle inserted through the chest wall to extract cells from a lung mass, guided by CT imaging. If fluid has accumulated around the lungs (called pleural effusion), doctors may sample this fluid to look for cancer cells. In some cases, surgeons perform a mediastinoscopy, inserting instruments through a small incision in the neck to sample lymph nodes in the center of the chest.[2]
The most reliable way to diagnose adenosquamous carcinoma is through examination of the entire tumor after surgical removal. According to the World Health Organization classification system, to be called adenosquamous carcinoma, the tumor must contain at least 10% of each cell type—both adenocarcinoma and squamous cell carcinoma components. Pathologists examine multiple sections of the tumor tissue to determine the proportions of each component and ensure the diagnosis is accurate.[1][4]
Molecular and Biomarker Testing
Once adenosquamous carcinoma has been confirmed through biopsy, additional laboratory tests on the tumor tissue become essential. These tests look for specific genetic changes or biomarkers (biological indicators) that can guide treatment decisions. For lung adenosquamous carcinoma, testing commonly includes looking for mutations in the EGFR gene (epidermal growth factor receptor), which is found in about 30% of these cancers. When present, EGFR mutations mean that targeted medications called EGFR-TKIs (tyrosine kinase inhibitors) such as erlotinib or gefitinib might be effective treatment options.[1][4]
Other important molecular tests include checking for ALK rearrangements (anaplastic lymphoma kinase gene changes), which occur in about 5% of adenosquamous carcinomas. When this genetic change is present, a medication called crizotinib may be helpful. Testing also typically includes measuring PD-L1 expression, a protein marker that helps predict whether immunotherapy treatments might work. Studies have found PD-L1 expression in about 11% of the adenocarcinoma component and 28% of the squamous component in these mixed tumors.[4]
These molecular tests are not just academic exercises—they directly impact treatment choices. For advanced stage IV disease, where surgery is often not possible, targeted therapies guided by these biomarkers can sometimes provide better results than traditional chemotherapy alone. The tests require special laboratory techniques and may take several days to complete, but the wait is worthwhile for the treatment guidance they provide.[1]
Distinguishing From Other Lung Cancers
Part of the diagnostic process involves making sure the cancer is truly adenosquamous carcinoma and not another type of lung cancer. Under the microscope, pathologists must distinguish this cancer from pure adenocarcinoma with some squamous features, pure squamous cell carcinoma with some glandular features, or what’s called a “collision tumor” where two separate cancers happen to be growing near each other. The distinction matters because treatment approaches and prognosis can differ.[4]
Pathologists use special staining techniques called immunohistochemistry to help identify the different cell types. These stains react with specific proteins in cancer cells, helping confirm whether cells are truly adenocarcinoma (which typically produce mucus and express certain markers) or squamous cell carcinoma (which show different protein patterns). This detailed analysis helps ensure patients receive the most appropriate treatment for their specific cancer type.[4]
Diagnostics for Clinical Trial Qualification
Clinical trials represent an important option for people with stage IV adenosquamous carcinoma, particularly because this rare cancer subtype means fewer established treatment protocols exist. However, entering a clinical trial requires meeting specific diagnostic criteria that researchers have established to ensure the study tests treatments on the right patient population. Understanding these requirements helps patients and doctors determine whether trial participation might be possible.[1]
Confirmed Histologic Diagnosis
Clinical trials for lung cancer almost always require pathologic confirmation—meaning a pathologist must have examined tumor tissue under a microscope and documented the specific cancer type. For adenosquamous carcinoma trials, researchers typically require written pathology reports showing that the tumor contains both adenocarcinoma and squamous cell carcinoma components in the proportions defined by the World Health Organization (at least 10% of each type). Some trials may require that tissue blocks or slides be sent to a central laboratory for independent review to confirm the diagnosis.[1][4]
Because preoperative biopsies so often miss the dual nature of adenosquamous carcinoma, patients whose initial biopsy showed only one cell type may need additional tissue sampling or surgical specimens reviewed before qualifying for certain trials. Researchers understand this challenge and some studies specifically allow enrollment based on surgical pathology even when earlier biopsies were inconclusive.[4]
Stage Confirmation and Disease Extent
Clinical trials categorize patients based on cancer stage and how far the disease has spread. For stage IV adenosquamous carcinoma trials, researchers require imaging documentation showing metastatic disease—meaning cancer has spread to distant organs or body sites. This typically means providing recent CT scans of the chest and abdomen, and often PET scans showing where active cancer exists throughout the body. Brain MRI scans are frequently required because lung cancer often spreads to the brain, and some treatments being tested might not cross into the brain effectively.[2]
The imaging must usually be performed within a specific timeframe before trial enrollment, typically within 4 to 6 weeks. This ensures that the information about disease extent is current and that the cancer hasn’t progressed significantly between screening and treatment start. Researchers also commonly require baseline measurements of all tumor sites that can be followed over time to determine if the experimental treatment is working.[2]
Biomarker Testing Requirements
Many modern clinical trials for advanced lung cancer require specific biomarker test results before enrollment. For adenosquamous carcinoma, trials might require documentation of EGFR mutation status, ALK rearrangement status, and PD-L1 expression levels. Some trials specifically seek patients whose tumors have certain mutations, while others might exclude patients with those mutations because approved targeted therapies already exist for them.[1][4]
For immunotherapy trials, PD-L1 testing becomes particularly important. The test measures what percentage of tumor cells express the PD-L1 protein on their surface. Trials might require minimum expression levels (such as PD-L1 expression on at least 1% or 50% of tumor cells) or might stratify patients into different treatment groups based on their expression levels. Because adenosquamous carcinoma shows different PD-L1 expression in its adenocarcinoma versus squamous components, the pathology report should specify which component was tested or provide overall tumor expression.[4]
Prior Treatment History
Clinical trial eligibility often depends on what treatments a patient has already received. Some trials accept only patients who have never been treated (called first-line trials), while others specifically seek patients whose cancer progressed despite one or more prior treatments. For stage IV adenosquamous carcinoma, researchers need documentation of any prior chemotherapy regimens, targeted therapies, immunotherapies, or radiation treatments, including dates, dosages, and how the cancer responded.[1]
Platinum-based chemotherapy (using drugs like cisplatin or carboplatin) represents standard initial treatment for stage IV adenosquamous carcinoma when targeted therapy options aren’t available. Trials testing second-line treatments typically require documentation that the cancer progressed during or after platinum chemotherapy. Some trials have specific waiting periods between the last dose of prior treatment and enrollment, allowing time for side effects to resolve.[1]
Performance Status and Laboratory Values
Beyond cancer-specific criteria, clinical trials require patients to meet certain health standards to ensure they can safely tolerate experimental treatments. Researchers assess performance status—a measure of how well patients can perform daily activities—using standardized scales. Most trials require that patients be able to care for themselves and be active for at least half their waking hours, even if they cannot work.[2]
Standard laboratory tests document organ function and overall health status. Typical requirements include blood tests showing adequate bone marrow function (sufficient red blood cells, white blood cells, and platelets), acceptable kidney function (measured by creatinine levels and calculated filtration rates), and adequate liver function (measured by bilirubin and liver enzyme levels). These tests ensure that patients can metabolize and clear the experimental medications safely and that their bodies can handle potential side effects.[2]
